Background In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of
esketamine nasal spray (ESK) in treatment-resistant depression (TRD)—short-term study …

Objective: Ketamine has been redeveloped as a rapid-acting antidepressant for treatment-
resistant depression (TRD). There is a paucity of literature comparing subanesthetic …

Background Patients with major depressive disorder who do not respond to≥ 2 different
pharmacological treatments within the current depressive episode are considered to have …

Abstract Introduction Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS)
are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies …

Objective: To compare esketamine to placebo, each in addition to standard-of-care
treatment, for rapidly reducing major depressive disorder symptoms, including suicidal …

Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, use
requirements, and place in therapy of esketamine for treatment-resistant depression (TRD) …

Abstract Background Treatment-resistant Depression (TRD) represents a widespread
disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer …

Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …

Intranasal form of esketamine, the S-enantiomer of racemic ketamine, was approved by the
US FDA in 2019 for treatment-resistant depression (TRD) in adults. Since intranasal …

Background Ketamine and its enantiomers have recently been highlighted as one of the
most effective therapeutic options in refractory depression. However, racemic ketamine and …